• 1
    Grant D. Intestinal transplantation. report of the international registry. Intestinal Transplant Registry. Transplantation 1999; 67: 10611064.
  • 2
    Sudan DK, Kaufman SS, Shaw BW Jr et al. Isolated intestinal transplantation for intestinal failure. Am J Gastroenterol 2000; 95: 15061515.
    Direct Link:
  • 3
    Farmer DG, McDiarmid SV, Yersiz H et al. Outcome after intestinal transplantation: results from one center's 9-year experience; discussion 1031–2. Arch Surg 2001; 136: 10271031.
  • 4
    Abu-Elmagd K, Reyes J, Bond G et al. Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg 2001; 234: 404417.
  • 5
    Nishida S, Levi D, Kato T et al. Ninety-five cases of intestinal transplantation at the University of Miami. J Gastrointest Surg 2002; 6: 233239.
  • 6
    Fishbein T, Kaufman S, Schiano T et al. Intestinal and multiorgan transplantation: the Mount Sinai experience. Transplant Proc 2002; 34: 891892.
  • 7
    Newell KA, He G, Hart J, Thistlethwaite JR Jr. Treatment with either anti-CD4 or anti-CD8 monoclonal antibodies blocks alphabeta T cell-mediated rejection of intestinal allografts in mice. Transplantation 1997; 64: 959965.
  • 8
    Newell KA, He G, Guo Z et al. Cutting edge: blockade of the CD28/B7 costimulatory pathway inhibits intestinal allograft rejection mediated by CD4+ but not CD8+ T cells. J Immunol 1999; 163: 23582362.
  • 9
    Guo Z, Meng L, Kim O et al. CD8 T cell-mediated rejection of intestinal allografts is resistant to inhibition of the CD40/CD154 costimulatory pathway. Transplantation 2001; 71: 13511354.
  • 10
    Owen RD. Immunogeneic consequences of vascular anastomoses between bovine twins. Science 1945; 102: 400401.
  • 11
    Billingham RE, Brent L, Medawar PB. ‘Actively acquired tolerance’ of foreign cells. Nature 1953; 172: 603606.
  • 12
    Main JM, Prehn RT. Successful skin homografts after the administration of high dosage X radiation and homologous bon marrow. J Natl Cancer Institute 1955; 15: 10231028.
  • 13
    Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168170.
  • 14
    Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169: 493502.
  • 15
    Wekerle T, Kurtz J, Ito H et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464469.
  • 16
    Durham MM, Bingaman AW, Adams AB et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 14.
  • 17
    Adams AB, Durham MM, Kean L et al. Costimulation blockade, busulfan, and bone marrow promote titratable macrochimerism, induce transplantation tolerance, and correct genetic hemoglobinopathies with minimal myelosuppression. J Immunol 2001; 167: 11031111.
  • 18
    Shirasugi N, Adams AB, Durham MM et al. Prevention of chronic rejection in murine cardiac allografts: a comparison of chimerism- and nonchimerism-inducing costimulation blockade-based tolerance induction regimens. J Immunol 2002; 169: 26772684.
  • 19
    Cagiannos C, Zhong R, Zang Z et al. Effect of major histocompatibility complex expression on murine intestinal graft survival. Transplantation 1998; 66: 13691374.
  • 20
    Parker DC, Greiner DL, Phillips NE et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A 1995; 92: 95609564.
  • 21
    Valujskikh A, Pantenburg B, Heeger PS. Primed allospecific T cells prevent the effects of costimulatory blockade on prolonged cardiac allograft survival in mice. Am J Transplant 2002; 2: 501509.
  • 22
    Tomita Y, Sachs DH, Khan A, Sykes M. Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation. Transplantation 1996; 61: 469477.
  • 23
    Wekerle T, Sayegh MH, Ito H et al. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non- myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation 1999; 68: 13481355.
  • 24
    Kawai T, Cosimi AB, Colvin RB et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 1995; 59: 256262.
  • 25
    Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB. Modifications of the conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997; 64: 709716.
  • 26
    He G, Hart J, Kim OS et al. The role of CD8 and CD4 T cells in intestinal allograft rejection: a comparison of monoclonal antibody-treated and knockout mice. Transplantation 1999; 67: 131137.
  • 27
    Orloff SL, Yin Q, Corless CL, Orloff MS, Rabkin JM, Wagner CR. Tolerance induced by bone marrow chimerism prevents transplant vascular sclerosis in a rat model of small bowel transplant chronic rejection. Transplantation 2000; 69: 12951303.
  • 28
    Wekerle T, Kurtz J, Sayegh M et al. Peripheral deletion after bone marrow transplantation with costimulatory blockade has features of both activation-induced cell death and passive cell death. J Immunol 2001; 166: 23112316.
  • 29
    Wekerle T, Kurtz J, Bigenzahn S, Takeuchi Y, Sykes M. Mechanisms of transplant tolerance induction using costimulatory blockade. Curr Opin Immunol 2002; 14: 592.
  • 30
    Russell PS, Chase CM, Sykes M, Ito H, Shaffer J, Colvin RB. Tolerance, mixed chimerism, and chronic transplant arteriopathy. J Immunol 2001; 167: 57315740.
  • 31
    Valujskikh A, Lantz O, Celli S, Matzinger P, Heeger PS. Cross-primed CD8 (+) T cells mediate graft rejection via a distinct effector pathway. Nat Immunol 2002; 3: 844851.
  • 32
    Larsen CP, Elwood ET, Alexander DZ et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434438.